Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD), Pathogenesis and Natural Product Gossipol for Prevention and Treatment

• 1. WHO . World Health Statistics Overview 2019: Monitoring Health for the SDGs, Sustainable Development Goals. Geneva: World Health Organization; (2019) (WHO/DAD/2019.1). Licence: CC BY-NC-SA 3.0 IGO. [Google Scholar]

2. Мирзаева А.Х. Корреляция между сердечно-сосудистыми заболеваниями и метаболическим синдромом и коррекция производным госсипола; (2025) 3:2 февраль 392-399. [Google Scholar]

• 3.Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

• 4.The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology Zobair Younossi MD, FACG , Joel E. Lavine MD, PhD , Anna Mae Diehl MD , Elizabeth M. Brunt MD ‖, Kenneth Cusi MD ¶, Michael Charlton MD ⁎⁎Volume 142, Issue 7, June 2012, Pages 1592-1609

• 5.Cook N., Geier A., Schmid A., et al. The patient perspectives on future therapeutic options in NASH and patient needs. FrontMed(Lausanne) 2019;6:61.

• 6.European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.

Мirzaeva А.Kh. +998997833755

adiba.mirzayeva@mail.ru ht tps.//orcid.org/0000-0002-8670-7431